Founded in 2006, IceCure's flagship system, ProSense™, uses ultrasound imaging to guide a small probe into the tumor and destroy it safely, quickly, and painlessly with liquid nitrogen. The system is available in the US, Europe, Hong-Kong, Thailand, Singapore, South-Central America, and Mainland China. ProSense™ is indicated for use in the fields of general surgery, oncology, gynecology, and urology. In 2021, ProSense™ was granted FDA Breakthrough Device Designation for the treatment of patients with T1 invasive breast cancer and/or patients not suitable for surgical alternatives for the treatment of breast cancer. IceCure is conducting the ICE3 Clinical Trial, the largest multi-center trial for cryoablation of small, low-risk breast cancer, and has presented promising results with only 2.06% of eligible trial patients experiencing cancer recurrence.